CBiPES
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-(4'-cyano-[1,1'-biphenyl]-3-yl-N-(3-pyridinylmethyl)ethanesulfonamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 856702-40-4  |
| ATC code | None |
| PubChem | CID 9864510 |
| ChemSpider | 8040202 |
| Chemical data | |
| Formula | C21H19N3O2S |
| Mol. mass | 377.459 g/mol |
|
|
|
|
CBiPES is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It has potentially antipsychotic effects in animal models, and is used for researching the role of mGluR2 receptors in schizophrenia and related disorders.[1][2][3]
References [edit]
- ^ Johnson, M. P.; Barda, D.; Britton, T. C.; Emkey, R.; Hornback, W. J.; Jagdmann, G. E.; McKinzie, D. L.; Nisenbaum, E. S. et al. (2005). "Metabotropic glutamate 2 receptor potentiators: Receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology 179 (1): 271–283. doi:10.1007/s00213-004-2099-9. PMID 15717213.
- ^ Fell, M. J.; Katner, J. S.; Johnson, B. G.; Khilevich, A.; Schkeryantz, J. M.; Perry, K. W.; Svensson, K. A. (2010). "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology 58 (3): 632–639. doi:10.1016/j.neuropharm.2009.11.014. PMID 19951716.
- ^ Sanger, H.; Hanna, L.; Colvin, E. M.; Grubisha, O.; Ursu, D.; Heinz, B. A.; Findlay, J. D.; Vivier, R. G. et al. (2012). "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology. doi:10.1016/j.neuropharm.2012.05.023. PMID 22659090.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
